Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Interventional study evaluating the efficacy of an immunotherapy (pembrolizumab) in
combination with a targeted therapy (vorinostat) in patient with recurrent and/or metastatic
squamous cell carcinoma (localisations : head and neck, lung, cervix, anus, vulva, and penis)